Crossmark

436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.436

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Mai, Haiqiang

Lin, Shaojun

Chen, Dongping

Chen, Xiaozhong

Qu, Song

Lin, Qin

Luo, Ying

Hu, Chunhong

Wu, Dehua

Qin, Tianxin

Jin, Feng

Chen, Nianyong

Luo, Yunxiu

Yao, Zhifang

Jin, Xiaoping

Li, Baiyong

Xia, Yu

Xu, Rui-Hua
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04220307 at ClinicalTrials.gov

Documents that mention this clinical trial

436 A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy
https://doi.org/10.1136/jitc-2021-sitc2021.436

Document is current

Any future updates will be listed below